Delirium Market

DelveInsight's "Delirium Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Delirium, historical and forecasted epidemiology as well as the Delirium market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Delirium market report provides current treatment practices, emerging drugs, Delirium market share of the individual therapies, current and forecasted Delirium market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Delirium treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Delirium market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Delirium Disease Understanding and Treatment Algorithm

The DelveInsight’s Delirium market report gives a thorough understanding of the Delirium by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Delirium Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Delirium.

Delirium Treatment

It covers the details of conventional and current medical therapies available in the Delirium market for the treatment of the condition. It also provides Delirium treatment algorithms and guidelines in the United States, Europe, and Japan.

Delirium Epidemiology 

The Delirium epidemiology section provides insights about the historical and current Delirium patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Delirium market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Delirium epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Delirium Epidemiology

The epidemiology segment also provides the Delirium epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Delirium Drug Chapters

The drug chapter segment of the Delirium report encloses the detailed analysis of Delirium marketed drugs and late-stage (Phase-III and Phase-II) Delirium pipeline drugs. It also helps to understand the Delirium clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Delirium Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Delirium treatment.

Delirium Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Delirium treatment.

Delirium Market Outlook

The Delirium market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Delirium market trends by analyzing the impact of current Delirium therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Delirium market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Delirium market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Delirium market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Delirium market in 7MM.

The United States Market Outlook

This section provides the total Delirium market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Delirium market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Delirium market size and market size by therapies in Japan is also mentioned.

Recent Development

• On November 2, 2026, Ceribell announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform. The technology combines seizure detection and delirium monitoring using a single EEG headband and AI-powered algorithms to continuously analyze brain activity. The launch follows the company's successful pilot across multiple hospitals and expands its neurological monitoring portfolio.
• On October 31, 2026, Peking Union Medical College Hospital initiated a clinical trial evaluating 40 Hz gamma auditory stimulation for preventing delirium in critically ill patients receiving mechanical ventilation. The multicentre, randomized, controlled study plans to enrol 142 participants and investigate whether auditory stimulation can increase delirium- and coma-free days during intensive-care treatment.
• On October 28, 2026, the DELIRE-ICU Phase II clinical study was listed as recruiting to evaluate melatonin for treating delirium in critically ill adult patients. Sponsored by CIUSSS de l'Est-de-l'Île-de-Montréal, the feasibility study plans to enrol 30 participants and assess the feasibility of conducting a larger randomized controlled trial of melatonin for delirium treatment.
• On September 30, 2026, Ceribell announced that the US FDA had granted 510(k) clearance for new quantitative EEG trending and amplitude-integrated EEG analysis software for its brain-monitoring platform. The development strengthens the company's neurological monitoring capabilities, building on its previously cleared delirium monitoring technology. However, this clearance is for additional EEG analysis capabilities, not a new delirium-specific indication.
• On September 5, 2026, the Canadian Clinical Trial Search Portal updated a Phase I/II clinical study evaluating dexmedetomidine in adults experiencing agitated delirium in palliative-care settings. The open-label study is designed to assess dose-finding, feasibility, and the potential effects of dexmedetomidine in managing agitation associated with delirium.
• On September 4, 2026, the University of Milano-Bicocca registered the CITADEL clinical trial to evaluate citicoline (TRAUSAN) for preventing cognitive decline following delirium in older adults with proximal hip fractures. The randomized study plans to enrol 122 participants and evaluate citicoline at 1,000 mg/day for six months compared with usual care. The programme expands clinical development into post-delirium cognitive recovery and management.
• On August 3, 2026, Ceribell announced that the U.S. Centers for Medicare & Medicaid Services (CMS) had granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare patient case utilizing its Delirium Monitor System. The reimbursement became effective October 1, 2026, helping eligible hospitals offset the cost of adopting the technology and potentially expanding access to AI-enabled delirium monitoring in critical-care settings.
• On June 16, 2026, the Australian New Zealand Clinical Trials Registry recorded a clinical study evaluating intranasal insulin compared with usual care for preventing delirium in critically ill patients. The study focuses on whether intranasal insulin can reduce delirium occurrence by day 14 or hospital discharge, potentially expanding therapeutic approaches for delirium prevention in intensive-care settings.
• On June 12, 2026, Cessatech announced a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance CT004, an intravenous melatonin-based treatment targeting post-anaesthesia agitation and emergence delirium in children. The collaboration supports the development and regulatory strategy for the treatment. The associated MELA-PAED Phase II clinical trial, involving 676 children across five Danish sites, was initiated in 2025.
• On June 4, 2026, Washington University School of Medicine updated its Phase II RIVA-AM clinical trial evaluating rivastigmine against placebo for the treatment of antimuscarinic delirium. The randomized, placebo-controlled study aims to determine whether rivastigmine can accelerate the resolution of agitation and delirium in patients experiencing antimuscarinic toxicity. The trial plans to enrol 42 participants, with completion expected in December 2028.
• On April 29, 2026, Washington University School of Medicine updated its Phase III clinical trial evaluating fluvoxamine for mitigating postoperative delirium in older adults undergoing non-cardiac surgery. The study investigates whether fluvoxamine can reduce postoperative delirium risk through its potential effects on neuroinflammation and brain activity. The trial is recruiting participants, with an estimated enrolment of 46 patients and primary completion expected in April 2027.
• On April 23, 2026, Duke University registered a Phase III clinical trial evaluating phenobarbital for the treatment of agitated delirium in adult patients admitted to intensive care units (ICUs). The study aims to determine whether phenobarbital can reduce ICU and hospital stays and the requirement for additional sedative medications compared with conventional therapy. The trial plans to enrol approximately 150 participants, with primary completion estimated for January 2027.
• On April 3, 2026, Duke University researchers published Phase II MARBLE trial results evaluating CN-105, an apolipoprotein E-mimetic peptide, for preventing postoperative delirium in older adults undergoing surgery. The trial involved 186 patients and reported postoperative delirium in 19.3% of patients receiving CN-105 compared with 26.5% in the placebo group. The treatment demonstrated a favourable safety and feasibility profile, supporting the need for further clinical evaluation in a larger Phase III study.
• On March 17, 2026, BioCina announced the initiation of a comprehensive Chemistry, Manufacturing, and Controls (CMC) program for RLS-2201, a proprietary injectable formulation of quetiapine developed by Patrys for the acute treatment of delirium in intensive care settings. The manufacturing activities are being conducted at BioCina's sterile manufacturing facility in Perth, Australia, to establish manufacturing consistency, product quality, and regulatory readiness. The collaboration strengthens the companies' efforts to advance an injectable treatment option for delirium.
• On December 9, 2025, Ceribell announced that the US FDA had granted 510(k) clearance for its proprietary Delirium Monitor System, designed to support delirium screening and monitoring through AI-powered EEG technology. The clearance marked an important regulatory milestone for the delirium diagnostics and monitoring market.

Delirium Drugs Uptake

This section focuses on the rate of uptake of the potential Delirium drugs recently launched in the Delirium market or expected to get launched in the market during the study period 2019-2032. The analysis covers Delirium market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Delirium Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Delirium market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Delirium Pipeline Development Activities

The Delirium report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Delirium key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Delirium report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Delirium emerging therapies.

Reimbursement Scenario in Delirium

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Delirium market trends, we take KOLs and SMEs ' opinion working in the Delirium domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Delirium market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Delirium Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Delirium, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Delirium epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Delirium is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Delirium market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Delirium market

Report Highlights

• In the coming years, the Delirium market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Delirium R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Delirium. The launch of emerging therapies will significantly impact the Delirium market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Delirium
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Delirium Report Insights

• Delirium Patient Population
• Therapeutic Approaches
• Delirium Pipeline Analysis
• Delirium Market Size and Trends
• Delirium Market Opportunities
• Impact of upcoming Delirium Therapies

Delirium Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Delirium Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Delirium Report Assessment

• Current Treatment Practices
• Unmet Needs
• Delirium Pipeline Product Profiles
• Delirium Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Delirium drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Delirium total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Delirium market size during the forecast period (2019-2032)?
• At what CAGR, the Delirium market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Delirium market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Delirium market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Delirium?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Delirium patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Delirium in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Delirium?
• Out of all 7MM countries, which country would have the highest prevalent population of Delirium during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Delirium treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Delirium in the USA, Europe, and Japan?
• What are the Delirium marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Delirium?
• How many therapies are in-development by each company for Delirium treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Delirium treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Delirium therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Delirium and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Delirium?
• What are the global historical and forecasted market of Delirium?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Delirium market
• To understand the future market competition in the Delirium market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Delirium in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Delirium market
• To understand the future market competition in the Delirium market